Umbilical cord blood plasma-derived exosomes as a novel therapy to reverse liver fibrosis

Abstract Background Cirrhosis is a chronic liver disease whereby scar tissue replaces healthy liver parenchyma, leading to disruption of the liver architecture and hepatic dysfunction. Currently, there is no effective disease-modifying therapy for liver fibrosis. Recently, our group demonstrated tha...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yu-Jen Huang, Jerry Cao, Chih-Yuan Lee, Yao-Ming Wu
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Cirrhosis Exosomes Hepatic stellate cells Inhibitor of DNA binding 1 Medicine (General) R5-920 Biochemistry QD415-436
Acceso en línea:	https://doaj.org/article/2a67964002e94c2e88009bbbf85cdeca
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2a67964002e94c2e88009bbbf85cdeca
record_format	dspace
spelling	oai:doaj.org-article:2a67964002e94c2e88009bbbf85cdeca2021-11-14T12:07:59ZUmbilical cord blood plasma-derived exosomes as a novel therapy to reverse liver fibrosis10.1186/s13287-021-02641-x1757-6512https://doaj.org/article/2a67964002e94c2e88009bbbf85cdeca2021-11-01T00:00:00Zhttps://doi.org/10.1186/s13287-021-02641-xhttps://doaj.org/toc/1757-6512Abstract Background Cirrhosis is a chronic liver disease whereby scar tissue replaces healthy liver parenchyma, leading to disruption of the liver architecture and hepatic dysfunction. Currently, there is no effective disease-modifying therapy for liver fibrosis. Recently, our group demonstrated that human umbilical cord blood (UCB) plasma possesses therapeutic effects in a rat model of acute liver failure. Methods In the current study, we tested whether exosomes (Exo) existed in UCB plasma and if they produced any antifibrotic benefits in a liver fibrosis model. Results Our results showed that UCB-Exo improved liver function and increased matrix metalloproteinase/tissue inhibitor of metalloproteinase degradation to reduce the degree of fibrosis. Moreover, UCB-Exo were found to suppress hepatic stellate cell (HSC) activity in vitro. These effects were associated with suppression of transforming growth factor-β/inhibitor of DNA binding 1 signaling. Conclusions These results further support that UCB-Exo have antifibrotic effects in mice with liver fibrosis and activated HSCs and may herald a new cell-free antifibrotic therapy.Yu-Jen HuangJerry CaoChih-Yuan LeeYao-Ming WuBMCarticleCirrhosisExosomesHepatic stellate cellsInhibitor of DNA binding 1Medicine (General)R5-920BiochemistryQD415-436ENStem Cell Research & Therapy, Vol 12, Iss 1, Pp 1-13 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Cirrhosis Exosomes Hepatic stellate cells Inhibitor of DNA binding 1 Medicine (General) R5-920 Biochemistry QD415-436
spellingShingle	Cirrhosis Exosomes Hepatic stellate cells Inhibitor of DNA binding 1 Medicine (General) R5-920 Biochemistry QD415-436 Yu-Jen Huang Jerry Cao Chih-Yuan Lee Yao-Ming Wu Umbilical cord blood plasma-derived exosomes as a novel therapy to reverse liver fibrosis
description	Abstract Background Cirrhosis is a chronic liver disease whereby scar tissue replaces healthy liver parenchyma, leading to disruption of the liver architecture and hepatic dysfunction. Currently, there is no effective disease-modifying therapy for liver fibrosis. Recently, our group demonstrated that human umbilical cord blood (UCB) plasma possesses therapeutic effects in a rat model of acute liver failure. Methods In the current study, we tested whether exosomes (Exo) existed in UCB plasma and if they produced any antifibrotic benefits in a liver fibrosis model. Results Our results showed that UCB-Exo improved liver function and increased matrix metalloproteinase/tissue inhibitor of metalloproteinase degradation to reduce the degree of fibrosis. Moreover, UCB-Exo were found to suppress hepatic stellate cell (HSC) activity in vitro. These effects were associated with suppression of transforming growth factor-β/inhibitor of DNA binding 1 signaling. Conclusions These results further support that UCB-Exo have antifibrotic effects in mice with liver fibrosis and activated HSCs and may herald a new cell-free antifibrotic therapy.
format	article
author	Yu-Jen Huang Jerry Cao Chih-Yuan Lee Yao-Ming Wu
author_facet	Yu-Jen Huang Jerry Cao Chih-Yuan Lee Yao-Ming Wu
author_sort	Yu-Jen Huang
title	Umbilical cord blood plasma-derived exosomes as a novel therapy to reverse liver fibrosis
title_short	Umbilical cord blood plasma-derived exosomes as a novel therapy to reverse liver fibrosis
title_full	Umbilical cord blood plasma-derived exosomes as a novel therapy to reverse liver fibrosis
title_fullStr	Umbilical cord blood plasma-derived exosomes as a novel therapy to reverse liver fibrosis
title_full_unstemmed	Umbilical cord blood plasma-derived exosomes as a novel therapy to reverse liver fibrosis
title_sort	umbilical cord blood plasma-derived exosomes as a novel therapy to reverse liver fibrosis
publisher	BMC
publishDate	2021
url	https://doaj.org/article/2a67964002e94c2e88009bbbf85cdeca
work_keys_str_mv	AT yujenhuang umbilicalcordbloodplasmaderivedexosomesasanoveltherapytoreverseliverfibrosis AT jerrycao umbilicalcordbloodplasmaderivedexosomesasanoveltherapytoreverseliverfibrosis AT chihyuanlee umbilicalcordbloodplasmaderivedexosomesasanoveltherapytoreverseliverfibrosis AT yaomingwu umbilicalcordbloodplasmaderivedexosomesasanoveltherapytoreverseliverfibrosis
_version_	1718429394785009664

Umbilical cord blood plasma-derived exosomes as a novel therapy to reverse liver fibrosis

Ejemplares similares